**Product Specification Sheet**

**Product Name:** SU6668 (Orantinib)

**Catalog Number:** C7866

**Technical information:**
- **Chemical Formula:** C_{18}H_{18}N_{2}O_{3}
- **CAS #:** 252916-29-3
- **Molecular Weight:** 310.35
- **Purity:** > 98%
- **Appearance:** Orange solid
- **Solubility:** Soluble in DMSO up to 100 mM
- **Chemical Name:** (2)-3-(2,4-dimethyl-5-((2-oxindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid
- **Storage:** Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.
- **Shelf Life:** In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.

**Handling:**
- To make 10 mM stock solution, add 0.322mL of DMSO for each mg of SU6668 (Orantinib).
- For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

**Biological Activity:**
SU-6668 (TSU-68) is an ATP-competitive, oxindole-based inhibitor of Flk-1/KDR, PDGFRbeta, and FGFR1 phosphorylation with Ki values of 2.1, 0.008, and 1.2 uM, respectively. [1] At these inhibitory levels, it was shown that SU-6668 induces antiangiogenic and proapoptotic effects in vivo. [2, 3]. Oral administration of SU6668 induced tumor regression in A431, PC-3, NCI-HT29, and Colo205 cell lines, and tumor stasis in SF767T glioma and NCI-H460 cell lines. [2]

In human myeloid leukemia cell lines and acute myeloid leukemia blasts, SU6668 was shown to inhibit the stem cell factor-induced phosphorylation of c-kit and ERK1/2 and induced apoptosis. [4]

**Reference:**
1. Laird et al., SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000, 60, 4152-4160. Pubmed ID: 10945623
2. Laird et al., SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB, 2002, 16(7), 681-690. Pubmed ID: 11978732
4. Smolich et al., The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood, 2001, 97, 1413-1421.

**To reorder:** [http://www.cellagentech.com/SU6668-Orantinib/](http://www.cellagentech.com/SU6668-Orantinib/)

**For Technical Support:** [technical@cellagentech.com](mailto:technical@cellagentech.com)

*Chemicals are sold for research use only, not for clinical or diagnostic use.*